David R. Bauer
Lawyers
Filters
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Intel $2.55 billion senior notes offering
The senior notes are due 2031, 2034 and 2054
Prime Medicine $161 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Market
Metagenomi $93.75 million IPO
The shares are listed on the Nasdaq Global Market
Tenaya Therapeutics $50 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Gilead Sciences $4.3 billion acquisition of CymaBay Therapeutics
We are advising Gilead Sciences on the acquisition
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
Ankura Consulting Group acquisition of Lumeri
We are advising Ankura on the acquisition
Bridgepoint sale of a minority interest in Humanetics
We are advising Bridgepoint and Humanetics on the transaction